The role of P2Y12 receptor and activated platelets during inflammation

Current Drug Targets

Volumn 15, Issue 7, 2014, Pages 720-728

  Liverani, Elisabetta ^a   Kilpatrick, Laurie E ^a   Tsygankov, Alexander Y ^a   Kunapuli, Satya P ^a,b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammation; Platelets and thienopyridines; Receptor

Indexed keywords

AR C66096; BETA,GAMMA DICHLOROMETHYLENE 2 PROPYLTHIOADENOSINE TRIPHOSPHATE; C REACTIVE PROTEIN; CANGRELOR; CARRIER PROTEINS AND BINDING PROTEINS; CD11B ANTIGEN; CD40 ANTIGEN; CLOPIDOGREL; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 6; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; JUNCTIONAL ADHESION MOLECULE C; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRASUGREL; PROTEIN KINASE C; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; RANTES; THIENOPYRIDINE DERIVATIVE; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; AUTACOID; PURINERGIC P2Y RECEPTOR ANTAGONIST;

DENDRITIC CELL; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; METABOLITE; NONHUMAN; PANCREATITIS; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TISSUE DISTRIBUTION; VASCULITIS; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THIENOPYRIDINES;

EID: 84904510632     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140519162133     Document Type: Review

References (105)

1. Italiano JE, Jr., Shivdasani RA. Megakaryocytes and beyond: the birth of platelets. J Thromb Haemost 2003; 1(6): 1174-82.
2. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1(7): 1602-12.
3. Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. Curr Opin Hematol 2009; 16(5): 329-33.
4. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8(11): 1227-34.
5. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010; 67(4): 499-511.
6. McMorran BJ, Marshall VM, de Graaf C, et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009; 323(5915): 797-800.
7. Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11(4): 264-74.
8. Quinton TM, Murugappan S, Kim S, Jin J, Kunapuli SP. Different G protein-coupled signaling pathways are involved in alpha granule release from human platelets. J Thromb Haemost 2004; 2(6): 978-84.
9. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54(8): 669-77.
10. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86(1): 222-32.
11. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3(2): 175-80.
12. Liu O, Jia L, Liu X, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One 2012; 7(12): e51707.
13. Hagiwara S, Iwasaka H, Hasegawa A, et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011; 35(3): 289-92.
14. Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharideinduced arthritis. PLoS One 2011; 6(10): e26035.
15. Mazzarello P, Calligaro AL, Calligaro A. Giulio Bizzozero: a pioneer of cell biology. Nat Rev Mol Cell Biol 2001; 2(10): 776-81.
16. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116(12): 3211-9.
17. Faraday N, Scharpf RB, Dodd-o JM, Martinez EA, Rosenfeld BA, Dorman T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94(1): 145-51.
18. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106(16): 2111-7.
19. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005; 25(11): 2428-34.
20. Sanguigni V, Ferro D, Pignatelli P, et al. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J Am Coll Cardiol 2005; 45(1): 35-42.
21. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94(5): 1931-6.
22. Asaduzzaman M, Lavasani S, Rahman M, et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37(4): 1389-96.
23. Liu Y, Gao XM, Fang L, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling fol lowing myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31(4): 834-41.
24. Hackert T, Sperber R, Hartwig W, et al. P-selectin inhibition reduces severity of acute experimental pancreatitis. Pancreatology 2009; 9(4): 369-74.
25. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92(3): 459-66.
26. Wrigley BJ, Shantsila E, Tapp LD, Lip GY. Increased formation of monocyte-platelet aggregates in ischemic heart failure. Circ Heart Fail 2012; 6(1): 127-35.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673): 245-52.
28. Kissel K, Berber S, Nockher A, Santoso S, Bein G, Hackstein H. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion 2006; 46(5): 818-27.
29. Langer HF, Daub K, Braun G, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol 2007; 27(6): 1463-70.
30. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98(12): 1164-71.
31. Boldt J, Muller M, Rothe A, Lenzen P, Hempelmann G. Does continuous heparinization influence platelet function in the intensive care patient? Intensive Care Med 1997; 23(5): 567-73.
32. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995; 25(11): 843-51.
33. Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost 2004; 2(12): 2096-102.
34. Russwurm S, Vickers J, Meier-Hellmann A, et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17(4): 263-8.
35. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104(13): 1533-7.
36. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105(3): 924-30.
37. Yang EY, Moses HL. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111(2): 731-41.
38. Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB. Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell 1984; 36(1): 35-41.
39. Meyer A, Wang W, Qu J, et al. Platelet TGF-beta1 contributions to plasma TGF-beta1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood 2012; 119(4): 1064-74.
40. Shi G, Field DJ, Long X, et al. Platelet factor 4 mediates vascular smooth muscle cell injury responses. Blood 2013; 121(21): 4417-27.
41. Hawrylowicz CM, Santoro SA, Platt FM, Unanue ER. Activated platelets express IL-1 activity. J Immunol 1989; 143(12): 4015-8.
42. Loppnow H, Bil R, Hirt S, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91(1): 134-41.
43. Hawrylowicz CM, Howells GL, Feldmann M. Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991; 174(4): 785-90.
44. Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J Immunol 2011; 186(9): 5489-96.
45. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154(3): 485-90.
46. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM. ADP receptors--targets for developing antithrombotic agents. Curr Pharm Des 2003; 9(28): 2303-16.
47. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95(14): 8070-4.
48. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273(4): 2030-4.
49. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 2006 Jul 18; 103(29): 11069-74.
50. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 2001; 108(3): 477-83.
51. Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 2009; 82(2): 261-71.
52. Garcia A, Kim S, Bhavaraju K, Schoenwaelder SM, Kunapuli SP. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010; 429(2): 369-77.
53. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. J Biol Chem 2002; 277(26): 23382-90.
54. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279(6): 4186-95.
55. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J Thromb Haemost 2006; 4(11): 2317-26.
56. Kim S, Kunapuli SP. P2Y12 receptor in platelet activation. Platelets 2011; 22(1): 54-8.
57. Quinton TM, Kim S, Jin J, Kunapuli SP. Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost 2005; 3(5): 1036-41.
58. Nagy B, Jr., Jin J, Ashby B, Reilly MP, Kunapuli SP. Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia. J Thromb Haemost 2011; 9(4): 810-9.
59. Morel O, El Ghannudi S, Hess S, et al. The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: Roles of white blood cell count and body weight. Thromb Haemost 2012; 108(2).
60. Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, Poole AW. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost 2008; 6(8): 1393-404.
61. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, Mundell SJ. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinasedependent mechanisms. Blood 2005; 105(9): 3552-60.
62. Mundell SJ, Jones ML, Hardy AR, et al. Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 2006; 70(3): 1132-42.
63. Remijn JA, Wu YP, Jeninga EH, et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22(4): 686-91.
64. Goto S, Tamura N, Eto K, Ikeda Y, Handa S. Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002; 105(21): 2531-6.
65. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98(12): 3340-5.
66. Nergiz-Unal R, Cosemans JM, Feijge MA, et al. Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. PLoS One 2010; 5(4): e10130.
67. Mendolicchio GL, Zavalloni D, Bacci M, et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2010; 9(2): 373-82.
68. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19(10): 2281-5.
69. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20(11): E101-6.
70. Marteau F, Le Poul E, Communi D, et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 2003; 64(1): 104-12.
71. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006; 110(3): 415-32.
72. Balduini A, Di Buduo CA, Malara A, et al. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica 2012; 97(11): 1657-65.
73. Wang L, Ostberg O, Wihlborg AK, Brogren H, Jern S, Erlinge D. Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 2003; 1(2): 330-6.
74. Sasaki Y, Hoshi M, Akazawa C, et al. Selective expression of Gi/ocoupled ATP receptor P2Y12 in microglia in rat brain. Glia 2003; 44(3): 242-50.
75. Wang L, Jacobsen SE, Bengtsson A, Erlinge D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5: 16.
76. Harada K, Matsumoto Y, Umemura K. Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 2011; 92(2): 148-54.
77. Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol 2010; 185(10): 5900-6.
78. Liverani E, Rico MC, Garcia AE, Kilpatrick LE, Kunapuli SP. Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther 2013; 344(1): 231-43.
79. Wihlborg AK, Wang L, Braun OO, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24(10): 1810-5.
80. Wang L, Olivecrona G, Gotberg M, Olsson ML, Winzell MS, Erlinge D. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ Res 2005; 96(2): 189-96.
81. Uehara K, Uehara A. P2Y1, P2Y6, and P2Y12 receptors in rat splenic sinus endothelial cells: an immunohistochemical and ultrastructural study. Histochem Cell Biol 2011; 136(5): 557-67.
82. Orriss IR, Burnstock G, Arnett TR. Purinergic signalling and bone remodelling. Curr Opin Pharmacol 2010; 10(3): 322-30.
83. Syberg S, Brandao-Burch A, Patel JJ, et al. Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 2012; 27(11): 2373-86.
84. Su X, Floyd DH, Hughes A, et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest 2012; 122(10): 3579-92.
85. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30(16): 1964-77.
86. Bhavaraju K, Mayanglambam A, Rao AK, Kunapuli SP. P2Y(12) antagonists as antiplatelet agents-Recent developments. Curr Opin Drug Discov Devel 2010; 13(4): 497-506.
87. Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42(2): 213-20.
88. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31(2): 195-204.
89. Kim YC, Lee JS, Sak K, et al. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol 2005; 70(2): 266-74.
90. Pfefferkorn JA, Choi C, Winters T, et al. P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett 2008; 18(11): 3338-43.
91. Becker RC. Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. J Thromb Thrombolysis 2009; 28(4): 513-4.
92. Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol 2012; 26(1): 19-26.
93. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001-15.
94. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 2003; 189(3): 233-46.
95. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007; 35(7): 1096-104.
96. Gremmel T, Kopp CW, Seidinger D, et al. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity. Atherosclerosis 2009; 207(2): 608-13.
97. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151(2): 521 e1-e4.
98. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33(4): 206-12.
99. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55(3): 780-4.
100. Waehre T, Damas JK, Pedersen TM, et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006; 4(10): 2140-7.
101. Winning J, Claus RA, Pletz MW, Bauer M, Losche W. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPSinduced systemic inflammation in a rat model. Shock 2011; 36(3): 317; author reply-8.
102. Kowal K, Pampuch A, Kowal-Bielecka O, DuBuske LM, Bodzenta-Lukaszyk A. Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy 2006; 36(4): 426-32.
103. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2010; 31(2): 153-64.
104. Schmitt-Sody M, Metz P, Gottschalk O, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007; 18(5): 365-72.
105. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327(5965): 580-3.